Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Evaluating the efficacy of RT-qPCR SARS-CoV-2 direct approaches in comparison to RNA extraction

Ofir Israeli\textsuperscript{a,\*}, Adi Beth-Din\textsuperscript{a}, Nir Paran\textsuperscript{b}, Dana Stein\textsuperscript{a}, Shirley Lazar\textsuperscript{a}, Shay Weiss\textsuperscript{a}, Elad Milrot\textsuperscript{a}, Yafit Atiya-Nasagi\textsuperscript{a}, Shmuel Yitzhaki\textsuperscript{c}, Orly Laskar\textsuperscript{d}, Ofir Schuster\textsuperscript{e}

\textsuperscript{a}Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona, Israel
\textsuperscript{b}Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel
\textsuperscript{c}Israel Institute for Biological Research, Ness Ziona, Israel

\section*{Article Info}

\textbf{Received 9 June 2020}
\textbf{Received in revised form 2 August 2020}
\textbf{Accepted 5 August 2020}

\section*{Abstract}

The genetic identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is based on viral RNA extraction prior to RT-qPCR assay. However, recent studies have supported the elimination of the extraction step. This study was performed to assess the necessity for the RNA extraction, by comparing the efficacy of RT-qPCR in several direct approaches versus the gold standard RNA extraction, in the detection of SARS-CoV-2 in laboratory samples, as well as in clinical oro-nasopharyngeal SARS-CoV-2 swabs. The findings showed an advantage for the extraction procedure; however a direct no-buffer approach might be an alternative, since it identified more than 60\% of positive clinical specimens.

© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

\section*{Introduction}

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant morbidity and mortality worldwide. At the time of writing, more than six million cases and over 370 000 deaths had been reported (Anon, 2020). The pandemic has created an acute need for rapid, cost-effective, and reliable diagnostic screening. The COVID-19 genetic diagnostics process includes RNA extraction from oro-nasopharyngeal swabs, followed by reverse transcriptase quantitative PCR (RT-qPCR) targeting viral genes (Corman et al., 2020). However, the global demand for reagents has placed extensive strain on supply chains for RT-qPCR kits, and to an even greater extent, on RNA isolation reagents. Potentially, eliminating RNA extraction would greatly simplify the diagnostic procedure, reducing both costs and the time to answer, while allowing testing to continue in the case of reagent shortages. Previous studies have demonstrated that several lysis buffers might allow the elimination of RNA extraction (Ladha et al., 2020; Pearson et al., 2020; Merindol et al., 2020). Very recently, two studies (Fomsgaard and Rosenstiehn, 2020; Bruce et al., 2020) used a direct no-buffer RT-qPCR approach, which identified <90\% of the tested clinical samples.

This study was performed to test the diagnostic efficiency following thermal inactivation (65 °C for 30 min and 95 °C for 10 min) without the addition of lysis buffer (‘no buffer’) or following lysis using one of three buffers (Virotype, QuickExtract, and 2\% Triton-X–100), and to make a comparison to diagnosis after standard RNA extraction. Samples included buffers spiked with SARS-CoV-2 at concentrations of 0.1–100 000 plaque-forming units (PFU)/mL and 30 clinical samples, previously diagnosed as positive (n = 20) and negative (n = 10).

\section*{Methods}

\subsection*{RNA standards and clinical samples}

Viral RNA standards were viable SARS-CoV-2 (GISAID accession number EPI_ISL_406862), cultured in Vero E6 cells and diluted in viral transport medium (Biological Industries). Virus concentrations were recorded in PFU/mL; 1 PFU was determined as 1000 virions by digital PCR (data not shown). Oro-nasopharyngeal swab samples for the study were selected after approval by conventional RT-qPCR. Positive and negative samples were randomly selected for this study and kept at 4 °C until use.

\subsection*{RNA extraction}

RNA was extracted from a 200-\textmu L sample using an RNAdvance Viral Kit and the Biomek i7 Automated Workstation (Beckman Coulter) and eluted with 50 \textmu L H\textsubscript{2}O.

\section*{Content lists available at ScienceDirect

International Journal of Infectious Diseases

\url{journal homepage: www.elsevier.com/locate/ijid

International Journal of Infectious Diseases}}
Direct detection

Samples were analyzed directly or mixed 1:1 with one of the following buffers: QuickExtract DNA Extraction Solution (Lucigen), Virotype Tissue Lysis Reagent (Indical Bioscience GmbH), and 2% Triton-X-100 (Sigma) after inactivation at 95 °C for 10 min or 65 °C for 30 min.

RT-qPCR

The RT-qPCR assays were performed using the SensiFAST Probe Lo-ROX One-Step Kit (Bioline). Primers and probe for the SARS-CoV-2 E gene were taken from the Berlin protocol (Corman et al., 2020).

Results and discussion

SARS-CoV-2 samples in different concentrations

Standard samples were analyzed in duplicate. The results are shown in Fig. 1, as averages. The samples were analyzed following two inactivation temperatures: 95 °C for 10 min or 65 °C for 30 min. The maximum standard deviation was <2 Ct, with an average standard deviation of 0.4 across all samples. The limit of detection was 1 PFU/mL. At this concentration, samples in the no-buffer mode and Virotype at 95 °C were not detected, while the RNA extraction mode averaged the lowest critical threshold (Ct = 29.8), followed by QuickExtract and Triton. At 10 PFU/mL, only the no-buffer mode at 95 °C failed to detect. The RNA

| Patient number | RNA extraction | Triton-X-100, 2% | QuickExtract | Virotype | No buffer |
|----------------|----------------|------------------|--------------|----------|----------|
|                | 65 °C 95 °C Δ  | 65 °C 95 °C Δ  | 65 °C 95 °C Δ | 65 °C 95 °C Δ | 65 °C 95 °C Δ |
| 1              | 17.0           | 31.9 15 31.3 14 | 18.6 1.5 20.4 3.4 | 23.7 6.6 24.2 7.1 | 18.3 1.2 21.9 4.8 |
| 2              | 19.5           | U – U – U – U – | 24.4 4.9 25.4 5.9 | 27.9 8.4 24.9 5.5 | 23.4 5.9 22.7 3.2 |
| 3              | 21.7           | U – U – U – U – | 31.4 9.8 30.9 9.3 | 33.8 12 30.5 8.9 | 28.5 6.8 27.9 6.3 |
| 4              | 28.8           | U – U – U – U – | 33.7 4.9 35.6 6.9 | 35.3 6.5 33.1 4.3 | 31.8 3 31.7 3 |
| 5              | 29.0           | U – U – U – U – | 33.7 4.7 35.4 6.4 | 38.7 9.8 35 6 | 32 3.1 32.5 3.6 |
| 6              | 29.6           | U – U – U – U – | 34 4.4 U – | 35.6 6 U – | 31.4 1.8 29.7 0.1 |
| 7              | 30.3           | U – U – U – U – | U – U – U – | U – U – | 39.1 8.8 35 4.7 |
| 8              | 30.3           | U – U – U – U – | 36.2 5 U – | U – U – | 35.2 4 35.3 4.1 |
| 9              | 31.2           | U – U – U – U – | U – 42.4 11 | U – 38.4 7 U – | 36.1 4.8 |
| 10             | 31.4           | U – U – U – U – | U – U – U – | U – U – | 35.8 4.2 |
| 11             | 31.6           | U – U – U – U – | U – U – U – | U – U – | 37.6 5.6 |
| 12             | 32.0           | U – U – U – U – | U – U – U – | U – U – | 38.8 6.8 |
| 13             | 32.4           | U – U – U – U – | 37.5 5.1 | 35.7 3.3 38.6 6.2 | 35.6 3.2 36.9 4.5 |
| 14             | 32.9           | U – U – U – U – | U – U – U – | U – U – | 38.3 5.4 U |
| 15             | 33.4           | U – U – U – U – | U – U – U – | U – U – | 43.1 15 U |
| 16             | 33.7           | U – U – U – U – | U – U – U – | U – U – | 34.9 1.5 |
| 17             | 33.8           | U – U – U – U – | U – U – U – | U – U – | U – U – |
| 18             | 35.7           | U – U – U – U – | 39.7 4 | U – U – U – | U – U – |
| 19             | 35.7           | U – U – U – U – | U – U – U – | U – U – | U – U – |
| 20             | 35.9           | U – U – U – U – | U – U – U – | U – U – | U – U – |

Detection level (%)

| Detection level (%) | 5 5 35 40 | 35 40 50 70 |

Ct, = cycle threshold; U = undetermined (Ct ≥ 45); Δ = the difference in Ct between RNA extraction and the different treatments.

a Detection level = the percentage of positive samples (Ct <45).
extraction mode maintained the lowest Ct values across all of the concentrations analyzed. The minimum ΔCt average to the RNA extraction mode was obtained using QuickExtract, followed by Triton, Viroteype, and the no-buffer mode.

SARS-CoV-2 clinical samples

Next we tested the feasibility of direct SARS-CoV-2 detection in clinical samples. Twenty positive and 10 negative samples were analyzed following thermal inactivation. All previously defined negative samples remained negative across the different buffers and test conditions. Positive samples exhibited major differences in detection capability (Table 1). The alternative buffers exhibited much lower detection levels: Triton (both inactivation protocols) detected a single positive sample (5% detection). QuickExtract and Viroteype had 35–40% detection rates (both inactivation protocols). Surprisingly, the direct no-buffer approach was superior, with 50% detection for the 65 °C inactivation protocol and 70% for the 95 °C inactivation protocol. Detection was reversely correlated to the sample Ct value, with efficiency dropping from 100% for Ct ≤ 32 to 25% for samples with higher Ct. The 95 °C no-buffer approach was further evaluated in a larger set of known positive samples, producing similar results (total n = 43, 63% detection).

Conclusions

The results of this study demonstrate that RNA extraction significantly improves comprehensive and sensitive clinical diagnosis of SARS-CoV-2. We suggest that clinical samples, which include a multitude of nucleic acids and proteins, might significantly hamper detection. Although previously reported to facilitate viral detection (Ladha et al., 2020; Pearson et al., 2020; Merindol et al., 2020), the buffers tested here severely compromised the limit of detection (to a maximum of 40%). This is surprising, considering that direct analysis without adding buffers achieved a 63% detection level. This no-buffer direct approach could potentially be used with some success in times of need to achieve screening for high-titer samples.

Funding source

No funding source is applicable to this study.

Ethical approval

Pre-existing samples were used and de-identified. This work was therefore determined to be research not involving human subjects.

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The SARS-CoV-2 was kindly provided by Bundeswehr Institute of Microbiology, Munich, Germany. The authors would like to thank Itai Ginirert for his helpful reviewing of this manuscript.

References

Anon https://www.worldometers.info/coronavirus/.
Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijnman L, Godekersi G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(January (3))2000045, doi:http://dx.doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.
Ladha A, Joung J, Abudayyeh O, Gootenberg J, Zhang F. A 5-min RNA preparation method for COVID-19 detection with RT-qPCR. medRxiv. 2020; 2020.05.07.20055947.
Pearson Joel D, Tricka Daniel, Hyduk Sharon J, Aynaud Marie-Ming, Javier Hernández J, Peidis Filippos, Lu Suying, Chan Kin, Woodgett Jim, Mazzuoli Tony, Attisano Liliana, Pelletier Laurence, Cybulskey Myron I, Wranja Jeffrey L, Bremnera Rod, Comparison of SARS-CoV-2 Indirect and Direct Detection Methods. BIORXIV 2020; , doi:http://dx.doi.org/10.1101/2020.05.12.092387.
Merindol N, Pépin G, Marchand C, Rheault M, Peterson C, Poirier A, Houle C, Germain H, Danylo AJ. SARS-CoV-2 detection by direct rRT-PCR without RNA extraction. Clin Virol. 2020;128(May 7)104423, doi:http://dx.doi.org/10.1016/j.cvi.2020.104423 Online ahead of print.PMID: 32416598 Free PMC article.
Fonsgaard AS, Rosenstrierne MW. An alternative workflow for molecular detection of 357 SARS-CoV-2 – escape from the NA extraction kit-shortage, Copenhagen, Denmark, March 358 2020 Euro Surveill. 25. 2020.
Bruce Emily A, Huang Mei-li, Perchetti Garrett A, Tighe Scott, Laugubhya Phoebe, Hoffman Jessica J, Gercard Diane L, Nalla Arun K, Wei Yuling, Greninger Alexander L, Diehl Sean A, Shirley David J, Leonard Debra GB, Huston Christopher D, Kirkpatrick Beth D, Dragon Julie A, Crothers Jessica W, Jerome Keith R, Botten Jason W. Direct RT-qPCR detection of SARS-CoV-2 RNA from patient nasopharyngeal swabs without an RNA extraction step. BIORXIV 2020; , doi:http://dx.doi.org/10.1101/2020.03.20.001008.